Skip to main content
Fig. 4 | BMC Urology

Fig. 4

From: Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations

Fig. 4

Kaplan Meier curve comparing OS for 55 patients from the next line of systemic therapy for kidney cancer after discontinuation of IO-VEGF by subsequent therapy: Cabozantinib vs. Axitinib vs. Other agents with no statistical difference among the three (Log-rank p = 0.25). OS (Overall Survival), IO-VEGF (Immune-Oncology and Vascular Endothelial Growth Factor targeted therapy)

Back to article page